Filing Details
- Accession Number:
- 0001104659-22-002722
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-10 16:07:48
- Reporting Period:
- 2022-01-06
- Accepted Time:
- 2022-01-10 16:07:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1802665 | Harmony Biosciences Holdings Inc. | HRMY | Pharmaceutical Preparations (2834) | 822279923 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821102 | Jeffrey Dierks | 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 | Chief Commercial Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-06 | 6,125 | $8.22 | 6,125 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-01-06 | 1,399 | $39.60 | 4,726 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-01-06 | 4,302 | $40.53 | 424 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-01-06 | 424 | $41.23 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Disposition | 2022-01-06 | 3,690 | $0.00 | 3,690 | $8.22 |
| Common Stock | Stock Option | Disposition | 2022-01-06 | 2,435 | $0.00 | 2,435 | $8.22 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 9,739 | 2027-10-02 | No | 4 | M | Direct | |
| 4,869 | 2028-10-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.04. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.07 to $41.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $41.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares on October 1, 2022.
- The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2022.
Billionaire Hedge Funds
